Key result
ViV-TAVR linked to ~18% lower absolute in-hospital mortality versus rSAVR.
Why the study?
Short-term outcomes of patients with failed aortic valve bioprosthesis undergoing valve-in-valve TAVR versus redo surgical aortic valve replacement were not well characterized.
Does ViV-TAVR reduce in-hospital all-cause mortality compared to rSAVR in patients with failed aortic valve bioprosthesis?
Cohort (n=90)
Does ViV-TAVR reduce in-hospital all-cause mortality compared to rSAVR in patients with failed aortic valve bioprosthesis?
Answers are grounded in this paper and cite their sources.
ViV-TAVR is associated with lower in-hospital mortality but higher rates of paravalvular leak compared to redo SAVR in patients with failed aortic bioprostheses.
Objective This study aimed to assess short-term outcomes of patients with failed aortic valve bioprosthesis undergoing valve-in-valve transcatheter aortic valve replacement (ViV-TAVR) or redo surgical aortic valve replacement (rSAVR). Methods Between 2009 and 2019, 90 patients who underwent ViV-TAVR (n = 73) or rSAVR (n = 17) due to failed aortic valve bioprosthesis fulfilled the inclusion criteria. Groups were compared regarding clinical end points, including in-hospital all-cause mortality. Patients with endocarditis and in a need of combined cardiac surgery were excluded from the study. Results ViV-TAVR patients were older (78.0 ± 7.4 vs. 62.1 ± 16.2 years, p = 0.012) and showed a higher prevalence of baseline comorbidities such as atrial fibrillation, diabetes mellitus, hyperlipidemia, and arterial hypertension. In-hospital all-cause mortality was higher for rSAVR than in the ViV-TAVR group (17.6 vs. 0%, p < 0.001), whereas intensive care unit stay was more often complicated by blood transfusions for rSAVR patients without differences in cerebrovascular events. The paravalvular leak was detected in 52.1% ViV-TAVR patients compared with 0% among rSAVR patients (p < 0.001). Conclusion ViV-TAVR can be a safe and feasible alternative treatment option in patients with degenerated aortic valve bioprosthesis. The choice of treatment should include the patient's individual characteristics considering ViV-TAVR as a standard of care.
No takes yet. Share an insight, caveat, or question.
Cizmic et al. (2021) conducted a cohort in Failed aortic valve bioprosthesis (n=90). Valve-in-valve transcatheter aortic valve replacement (ViV-TAVR) vs. Redo surgical aortic valve replacement (rSAVR) was evaluated on In-hospital all-cause mortality (p=<0.001). Valve-in-valve TAVR was associated with lower in-hospital all-cause mortality compared to redo surgical aortic valve replacement.
Synapse has enriched 10 related papers. Consider them for comparative context: